about
Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesAutoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's diseaseWorking the endless puzzle of hereditary autoinflammatory disorders.Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.Biological treatments in Behçet's disease: beyond anti-TNF therapy.Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis.The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study.Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort.Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issuesThe use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infectionOsteoporosis and psoriatic arthritis.Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab.Efficacy of tocilizumab in a patient with refractory psoriatic arthritis.Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome.The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy.Untangling the web of systemic autoinflammatory diseases.Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease.Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis.Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.The Definition and Measurement of Axial Psoriatic Arthritis.Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.Emerging drugs for psoriatic arthritis.Psoriatic arthritis and psoriasis: differential diagnosis.Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients.Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-α therapy.PFAPA syndrome and Behçet's disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists.Safety profile of biologic agents for Behçet's disease in a multicenter observational cohort study.Dactylitis in enteropathic spondyloarthritis.Fragility Fractures in Patients with Psoriatic Arthritis.Psoriatic Disease: Clinical Staging.Simple clinical indicators for early psoriatic arthritis detection.Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients.Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia.Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.The ClASsification for Psoriatic ARthritis (CASPAR) criteria--a retrospective feasibility, sensitivity, and specificity study.Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis.
P50
Q26777084-C705258E-E036-4D3D-A457-BE61D7FF9925Q26778253-1AFF0959-DFA7-4AFD-A5AB-41647E2EC1BAQ33357128-65A840B0-ABC1-48D2-88D8-512DA8C4D2A6Q33387811-0B59E489-C0E2-413F-AB60-E131BFA3F86BQ33908217-FC0633E3-20F5-4807-8FC2-A6FC5943CD2CQ33993099-A52C8A6C-2415-4775-9B0E-00424DC9C012Q34443117-877F0A9E-778D-4DE3-9879-B45CCD20B554Q35132212-D09B8448-6178-4BCA-BDA3-DE63154808FFQ36009390-E8E5D7F5-5157-43A4-8517-3C0A28FC0B15Q37299354-8E4CCAEC-EF81-45B9-BC0F-AD656ED0C8C0Q37655910-E26EEEB3-E2AC-4C2A-B9CF-E31157BBA66BQ38023168-85A8EA84-1D0B-49B7-8838-17BA888E721FQ38097750-79543948-1095-485C-B167-AED659C9CA0CQ38202538-FC33BC5B-C39A-46F7-86CC-CBA938A8E94CQ38220758-A106C02D-DFA4-4EAB-8AB4-992FB496416EQ38222307-9B15C4FE-C67A-4C33-8E80-15712BDCE66EQ38240838-16D08399-1D19-4AE5-9410-B0242329D18BQ38242729-A8D647EF-4DC8-4F4F-AC22-A88B7E861A71Q38245566-5B69CE3F-F75B-4243-8AFE-22DD628AE1FFQ38344512-63D004AD-2737-42AF-8D65-8DBDF3E51B59Q38622059-C0437187-DC28-4AA5-B73B-5A67C76512F3Q38622088-8BD48FE8-F14A-4EEB-9616-A8D570D89CCBQ38630548-29E019C7-6B09-4985-99D6-5C4A94AD6DFDQ38710642-42FA00C6-C350-432A-852F-47DE3D3F4DF9Q38828427-00B5DAA4-04C5-46A4-A60A-C89CE68C45ACQ38856226-D0C1F8AD-A701-4B69-A2AF-05346043ADF2Q39748097-8EC75165-15C8-44CF-A972-55EB7BBB67E2Q39861020-49B8909F-0E26-49B9-ACD9-162D8657B58AQ39929264-CC95D2F7-E543-42FC-9FF2-1D73D3724184Q40170236-778F7255-C9C4-4CBC-A46C-34886EB3C554Q40630984-C287DF62-1D83-4C31-8607-22F74CF25C3EQ40795399-419E455F-BE7F-4653-92CC-9C45ADB2521FQ41160242-40E53269-8439-4254-9ED0-EC71CD6DCFDCQ41160257-82B14A00-7BC7-4D42-8254-6A412D871D98Q41446342-98DB919B-7C16-49C4-982C-AE07B806F3A0Q42274394-C20A3FCC-E280-4F65-B43D-90D5B8923EDDQ42632287-859151D0-275E-4506-9B56-7A3ECE746841Q43727420-9CA0583E-2D08-46EA-BFC7-2BE768DF428FQ43955638-327A5BE8-900D-4FC2-823E-1C20E6210E95Q44732015-843062FA-D889-42F7-870C-8A00C254F1C5
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Luisa Costa
@ast
Luisa Costa
@en
Luisa Costa
@es
Luisa Costa
@nl
Luisa Costa
@sl
Луиза Коста
@ru
type
label
Luisa Costa
@ast
Luisa Costa
@en
Luisa Costa
@es
Luisa Costa
@nl
Luisa Costa
@sl
Луиза Коста
@ru
prefLabel
Luisa Costa
@ast
Luisa Costa
@en
Luisa Costa
@es
Luisa Costa
@nl
Luisa Costa
@sl
Луиза Коста
@ru
P106
P21
P31
P496
0000-0001-7022-9685